AB vs ERAS Comparison

AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of February 2026, the company had $880.0 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (40%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.